The recent deal between Meiragtx Holdings plc and New Brunswick, N.J.-based Johnson & Johnson (J&J) arm Janssen Pharmaceuticals Inc. drew more eyeballs to companies targeting inherited retinal diseases (IRDs), which can only mean good things for the likes of Nightstar Therapeutics plc.